BACKGROUND: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known. METHODS: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF, BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1. RESULTS: Although the overall frequency of CpG island promoter methylation events increased with age (P<0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P=0.051), INK4a/ARF (P=0.042), HIN-1 (P=0.044), and PRA (P=0.032), as well as the overall frequency of methylation events (P=0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had <or=4 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P<0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters. CONCLUSIONS: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2 familial breast cancer.
BACKGROUND: Only 5% of all breast cancers are the result of BRCA1/2 mutations. Methylation silencing of tumor suppressor genes is well described in sporadic breast cancer; however, its role in familial breast cancer is not known. METHODS: CpG island promoter methylation was tested in the initial random periareolar fine-needle aspiration sample from 109 asymptomatic women at high risk for breast cancer. Promoter methylation targets included RARB (M3 and M4), ESR1, INK4a/ARF, BRCA1, PRA, PRB, RASSF1A, HIN-1, and CRBP1. RESULTS: Although the overall frequency of CpG island promoter methylation events increased with age (P<0.0001), no specific methylation event was associated with age. In contrast, CpG island methylation of RARB M4 (P=0.051), INK4a/ARF (P=0.042), HIN-1 (P=0.044), and PRA (P=0.032), as well as the overall frequency of methylation events (P=0.004), was associated with abnormal Masood cytology. The association between promoter methylation and familial breast cancer was tested in 40 unaffected premenopausal women in our cohort who underwent BRCA1/2 mutation testing. Women with BRCA1/2 mutations had a low frequency of CpG island promoter methylation (15 of 15 women had <or=4 methylation events), whereas women without a mutation showed a high frequency of promoter methylation events (24 of 25 women had 5-8 methylation events; P<0.0001). Of women with a BRCA1/2 mutation, none showed methylation of HIN-1 and only 1 of 15 women showed CpG island methylation of RARB M4, INK4a/ARF, or PRB promoters. CONCLUSIONS: This is the first evidence of CpG island methylation of tumor suppressor gene promoters in non-BRCA1/2familial breast cancer.
Authors: M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman Journal: J Natl Cancer Inst Date: 2000-04-05 Impact factor: 13.506
Authors: M Widschwendter; J Berger; M Hermann; H M Müller; A Amberger; M Zeschnigk; A Widschwendter; B Abendstein; A G Zeimet; G Daxenbichler; C Marth Journal: J Natl Cancer Inst Date: 2000-05-17 Impact factor: 13.506
Authors: M Widschwendter; J Berger; G Daxenbichler; E Müller-Holzner; A Widschwendter; A Mayr; C Marth; A G Zeimet Journal: Cancer Res Date: 1997-10-01 Impact factor: 12.701
Authors: Jennifer D Brooks; Paul Cairns; Roy E Shore; Catherine B Klein; Isaac Wirgin; Yelena Afanasyeva; Anne Zeleniuch-Jacquotte Journal: Cancer Epidemiol Date: 2010-12 Impact factor: 2.984
Authors: James M Flanagan; Sibylle Cocciardi; Nic Waddell; Cameron N Johnstone; Anna Marsh; Stephen Henderson; Peter Simpson; Leonard da Silva; Kumkum Khanna; Sunil Lakhani; Chris Boshoff; Georgia Chenevix-Trench Journal: Am J Hum Genet Date: 2010-03-04 Impact factor: 11.025
Authors: Patrick G Pilie; Catherine Ibarra-Drendall; Michelle M Troch; Gloria Broadwater; William T Barry; Emanuel F Petricoin; Julia D Wulfkuhle; Lance A Liotta; Siya Lem; Joseph C Baker; April Stouder; Anne C Ford; Lee G Wilke; Carola M Zalles; Priya Mehta; Jamila Williams; Melanie Shivraj; Zuowei Su; Joseph Geradts; Dihua Yu; Victoria L Seewaldt Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-17 Impact factor: 4.254
Authors: Vered Stearns; Mary Jo Fackler; Seema A Khan; Saraswati Sukumar; Sidra Hafeez; Zoila Lopez Bujanda; Robert T Chatterton; Lisa K Jacobs; Nagi F Khouri; David Ivancic; Kara Kenney; Christina Shehata; Stacie C Jeter; Judith A Wolfman; Carola M Zalles; Peng Huang Journal: Cancer Prev Res (Phila) Date: 2016-06-03
Authors: Nadine Tung; Alexander Miron; Stuart J Schnitt; Shiva Gautam; Katharina Fetten; Jennifer Kaplan; Yosuf Yassin; Ayodele Buraimoh; Ji-Young Kim; Attila M Szász; Ruiyang Tian; Zhigang C Wang; Laura C Collins; Jane Brock; Karen Krag; Robert D Legare; Dennis Sgroi; Paula D Ryan; Daniel P Silver; Judy E Garber; Andrea L Richardson Journal: Breast Cancer Res Date: 2010-11-16 Impact factor: 6.466